Clinical Trial Update: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

A Phase 2 trial of Selinexor (KPT-330) for relapsed or refractory diffuse large B-cell lymphoma is currently recruiting. No trial results are reported yet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: RECRUITING